Jalal Shakeri1, Vahid Farnia1, Ali Reza Karimi1, Faeze Tatari1, Touraj Ahmadi Juibari1, Mostafa Alikhani1, Hafez Bajoghli2, Edith Holsboer-Trachsler3, Serge Brand4. 1. Substance Abuse Prevention Research Center, Psychiatry Department, Kermanshah University of Medical Sciences, Kermanshah, Iran. 2. Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran. 3. Psychiatric Clinics of the University of Basel, Center for Affective, Stress and Sleep Disorders, Basel, Switzerland. 4. Psychiatric Clinics of the University of Basel, Center for Affective, Stress and Sleep Disorders, Basel, Switzerland; Department of Sport, Exercise and Health, Sport Science Section, Faculty of Medicine, University of Basel, Basel, Switzerland. Electronic address: serge.brand@upkbs.ch.
Abstract
BACKGROUND: Amphetamine abuse is increasing worldwide, and the occurrence of amphetamine-induced (AI) psychiatric issues further complicates treatment. In response, the DSM 5 has introduced the classification of amphetamine-induced obsessive-compulsive disorders (AI-OCD), though little has been published on either its prevalence rates or its clinical features. The aim of the present study was therefore to investigate the prevalence of AI-OCD, to describe patients' clinical features, and to compare the prevalence rate among such patients with those for OCD in the general population in Western countries and Iran. METHODS: A total of 547 patients with amphetamine abuse or dependency and with a positive urine test (mean age: 31.64 years; 75.5% males) took part in the study. A psychiatric interview was carried out, covering both socio-demographic and illness-related information. RESULTS: 18 (3.3%) patients suffered from OCD prior to amphetamine abuse, 491 (89.8%) had no OCD, and 38 (6.9%) suffered from AI-OCD. Neither socio-demographic nor illness-related dimensions predicted patients with diagnosed AI-OCD. The prevalence of AI-OCD was significantly higher than that for OCD in the general population (2.3% in Western countries, 1.8% in Iran). CONCLUSIONS: Data suggest that prevalence rate of AI-OCD is about 7%. Neither socio-demographic nor illness-related dimensions predicted the occurrence of AI-OCD. Thus, it remains unclear why some amphetamine abusers develop AI-OCD while others do not.
BACKGROUND:Amphetamine abuse is increasing worldwide, and the occurrence of amphetamine-induced (AI) psychiatric issues further complicates treatment. In response, the DSM 5 has introduced the classification of amphetamine-induced obsessive-compulsive disorders (AI-OCD), though little has been published on either its prevalence rates or its clinical features. The aim of the present study was therefore to investigate the prevalence of AI-OCD, to describe patients' clinical features, and to compare the prevalence rate among such patients with those for OCD in the general population in Western countries and Iran. METHODS: A total of 547 patients with amphetamine abuse or dependency and with a positive urine test (mean age: 31.64 years; 75.5% males) took part in the study. A psychiatric interview was carried out, covering both socio-demographic and illness-related information. RESULTS: 18 (3.3%) patients suffered from OCD prior to amphetamine abuse, 491 (89.8%) had no OCD, and 38 (6.9%) suffered from AI-OCD. Neither socio-demographic nor illness-related dimensions predicted patients with diagnosed AI-OCD. The prevalence of AI-OCD was significantly higher than that for OCD in the general population (2.3% in Western countries, 1.8% in Iran). CONCLUSIONS: Data suggest that prevalence rate of AI-OCD is about 7%. Neither socio-demographic nor illness-related dimensions predicted the occurrence of AI-OCD. Thus, it remains unclear why some amphetamine abusers develop AI-OCD while others do not.
Authors: Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Emma S Rathkey; Alison McCallum Journal: Exp Clin Psychopharmacol Date: 2016-10 Impact factor: 3.157
Authors: Sharful Islam Khan; Mohammad Niaz Morshed Khan; Samira Dishti Irfan; A M Rumayan Hasan; Allen G Ross; Lily Ming-Sha Horng; Nathan Lachowsky; Gail Knudson; Tasnim Azim Journal: Arch Sex Behav Date: 2020-04-01
Authors: Jeremy Veenstra-VanderWeele; Susanne E Ahmari; Muhammad O Chohan; Jared M Kopelman; Hannah Yueh; Zeinab Fazlali; Natasha Greene; Alexander Z Harris; Peter D Balsam; E David Leonardo; Edgar R Kramer Journal: Mol Psychiatry Date: 2022-01-20 Impact factor: 13.437